Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Teva Pharmaceuticals (NYSE: TEVA) presented positive real-world survey data for AUSTEDO XR® (deutetrabenazine) at the 2025 Psych Congress Annual Meeting. The survey of 209 tardive dyskinesia (TD) patients showed remarkable treatment satisfaction, with over 94% reporting movement improvement and more than 89% expressing high satisfaction with the treatment.
Key findings revealed that 77% of patients reported improved social comfort and emotional well-being, while 96% found the medication easy to take. The study included both patients with prior valbenazine use and those without prior treatment, with 96% of participants expressing interest in continuing AUSTEDO XR treatment.
Teva Pharmaceuticals (NYSE: TEVA) ha presentato dati positivi di sondaggio nel mondo reale per AUSTEDO XR® (deutetrabenazine) al 2025 Psych Congress Annual Meeting. L'indagine su 209 pazienti con tardiva dyskinesia (TD) ha mostrato una notevole soddisfazione del trattamento, con oltre il 94% che riferisce un miglioramento del movimento e più del 89% esprime un'alta soddisfazione per il trattamento.
I principali risultati hanno rivelato che il 77% dei pazienti ha riportato un miglioramento del comfort sociale e del benessere emotivo, mentre il 96% ha trovato facile assumere il farmaco. Lo studio ha incluso sia pazienti con precedente utilizzo di valbenazina che quelli senza trattamento precedente, con il 96% dei partecipanti interessato a proseguire il trattamento con AUSTEDO XR.
Teva Pharmaceuticals (NYSE: TEVA) presentó datos positivos del mundo real de AUSTEDO XR® (deutetrabenazine) en la 2025 Psych Congress Annual Meeting. la encuesta de 209 pacientes con discinesia tardía (TD) mostró una satisfacción notable con el tratamiento, con más del 94% reportando mejora del movimiento y más de 89% expresando una gran satisfacción con el tratamiento.
Entre los hallazgos clave, el 77% de los pacientes reportó una mejora en la comodidad social y el bienestar emocional, mientras que el 96% consideró fácil tomar el medicamento. El estudio incluyó tanto pacientes con uso previo de valbenazina como sin tratamiento previo, con el 96% de los participantes expresando interés en continuar con el tratamiento AUSTEDO XR.
테바 파마슈티컬스(NYSE: TEVA)는 2025 Psych Congress Annual Meeting에서 AUSTEDO XR®(deutetrabenazine)에 대한 실제 세계 설문 데이터를 발표했습니다. TD(지연성 운동장애) 환자 209명를 대상으로 한 설문은 치료에 대한 탁월한 만족도를 보였으며, 이동 개선을 보고한 비율이 94% 이상, 그리고 치료에 대해 높은 만족감을 표현한 사람이 89% 이상이었습니다.
주요 결과로는 환자의 77%가 사회적 편안함과 정서적 안녕의 개선을 보고, 약 복용이 쉽다고 평가한 비율이 96%로 나타났습니다. 연구에는 이전발 벨벤자민(valbenazine) 사용 여부와 무관하게 TD 환자들이 포함되었고, 참가자의 96%가 AUSTEDO XR 치료를 계속할 의향이 있다고 표현했습니다.
Teva Pharmaceuticals (NYSE: TEVA) a présenté des données positives du monde réel pour AUSTEDO XR® (deutetrabenazine) lors de la Psych Congress Annual Meeting 2025. L’enquête auprès de 209 patients atteints de Dyskinésie Tardive (TD) a montré une satisfaction du traitement remarquable, avec plus de 94% déclarant une amélioration des mouvements et plus de 89% exprimant une grande satisfaction du traitement.
Les résultats clés ont révélé que 77% des patients ont signalé une amélioration du confort social et du bien-être émotionnel, tandis que 96% ont trouvé le médicament facile à prendre. L’étude comprenait à la fois des patients ayant utilisé préalablement le véland-benazine (valbenazine) et des patients sans traitement antérieur, avec 96% des participants exprimant leur intérêt à poursuivre le traitement AUSTEDO XR.
Teva Pharmaceuticals (NYSE: TEVA) präsentierte positive Real-World-Daten für AUSTEDO XR® (Deutetrabenazin) auf dem 2025 Psych Congress Annual Meeting. Die Umfrage unter 209 TD-Patienten zeigte bemerkenswerte Behandlungszufriedenheit, wobei über 94% eine Bewegungsverbesserung berichteten und mehr als 89% eine hohe Zufriedenheit mit der Behandlung äußerten.
Wichtige Ergebnisse zeigten, dass 77% der Patienten eine verbesserte soziale Wohlbefinden und emotionales Wohlbefinden angaben, während 96% das Medikament als einfach einzunehmen empfanden. Die Studie schloss sowohl Patienten mit vorheriger Valbenazinhilfe als auch solche ohne vorherige Behandlung ein, wobei 96% der Teilnehmer Interesse bekundeten, die AUSTEDO XR-Therapie fortzusetzen.
Teva Pharmaceuticals (NYSE: TEVA) قدمت بيانات استقصائية واقعية إيجابية لـ AUSTEDO XR® (دووتاترابينازين) في اجتماع Psych Congress السنوي 2025. أظهرت الاستطلاعات التي شملت 209 مريضاً باضطراب الحركة التأخري TD رضا ملحوظاً عن العلاج، حيث أبلغ أكثر من 94% عن تحسن في الحركة، وأكثر من 89% يعبرون عن رضا عالي عن العلاج.
كشفت النتائج الرئيسية أن 77% من المرضى أبلغوا عن تحسن في الراحة الاجتماعية والصحة العاطفية، بينما وجد 96% أن الدواء سهل الاستعمال. وتضمنت الدراسة مرضى سبق لهم استخدام فالبنزاين (valbenazine) وآخرين ليس لديهم علاج سابق، مع إعراب 96% من المشاركين عن رغبتهم في استمرار علاج AUSTEDO XR.
Teva Pharmaceuticals (NYSE: TEVA) 在 2025 年 Psych Congress 年度会议上展示了 AUSTEDO XR®（deutetrabenazine）的真实世界调查数据。对 209 例迟发性运动障碍（TD）患者 的调查显示治疗满意度显著，超过 94% 报告运动改善，且有超过 89% 表示对治疗高度满意。
主要发现显示，77% 的患者报告在社会舒适感和情绪健康方面的改善，而 96% 认为药物易于服用。研究包括既有 valbenazine 使用史的患者，也有未曾治疗的患者，96% 的参与者表示有继续使用 AUSTEDO XR 治疗的意愿。
- Over 94% of patients reported movement improvement with AUSTEDO XR
- High patient satisfaction rates exceeding 89%
- 96% of patients expressed interest in continuing treatment
- More than 77% reported improved social comfort and emotional well-being
- Strong ease of use with over 96% reporting medication was easy to take
- None.
Insights
Teva's AUSTEDO XR shows strong patient satisfaction and symptom improvement in real-world survey, strengthening its position in the TD treatment market.
Teva's announcement of real-world patient survey data for AUSTEDO XR (deutetrabenazine) extended-release tablets provides compelling evidence of the medication's effectiveness in treating tardive dyskinesia (TD). The survey of 209 patients revealed remarkably high satisfaction rates, with over 94% reporting movement improvement and over 89% expressing overall satisfaction with the treatment.
What's particularly noteworthy is that these positive results were consistent across both patient groups studied - those with prior valbenazine use (PVU) and those with no prior treatment (de novo). The fact that 96% of patients expressed interest in continuing treatment suggests strong patient retention potential, a crucial factor for sustained market performance.
Beyond the physical symptom improvements, the data demonstrates AUSTEDO XR's impact on quality of life metrics, with over 77% of patients reporting increased comfort in social settings and improved emotional well-being. This holistic benefit profile strengthens the medication's value proposition in a competitive market.
The high ease-of-use rating (over 96%) and patient appreciation for dose adjustment flexibility (over 82%) highlight the practical advantages of AUSTEDO XR's formulation. These factors can drive patient preference and adherence, potentially differentiating AUSTEDO XR from competitors in the TD treatment landscape.
This real-world evidence complements clinical trial data and provides healthcare providers with valuable insights into patient experiences, potentially supporting broader adoption of AUSTEDO XR in clinical practice. The data presentation at the Psych Congress Annual Meeting ensures visibility among key prescribers, which could translate to prescription growth for this important product in Teva's neurology portfolio.
- Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >
94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tablets - Patients reported high satisfaction (>
89% ) with AUSTEDO XR, with96% expressing interest in continuing treatment - Almost all (>
96% ) patients relayed that AUSTEDO XR was easy to take
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR. The data were presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025 in San Diego, California.
"When we look at tardive dyskinesia, it’s not just the science or the data, but the real people who are facing the daily physical and emotional challenges of this disease,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “At Teva, we feel a profound responsibility to ensure we’re not just treating TD with the benefits that AUSTEDO XR can bring, but truly understanding the lived experiences of this community. It’s our duty to keep pushing forward to innovate with the ultimate goal of giving these individuals back the freedom they deserve.”
The noninterventional, prospective, cross-sectional survey included 209 participants with TD, 54 of whom had prior valbenazine use (PVU) and 100 who were on no prior treatment (de novo).
Key results revealed that both groups:
- stated their uncontrollable movements were very much, much, or minimally improved once treated with AUSTEDO XR (>
94% ) - strongly agreed or agreed that since starting AUSTEDO XR their reduction in movements led to more comfort in social settings and improved emotional well-being (>
77% ) - liked that their provider could adjust their dose (≥
82% ) - reported it was easy to take AUSTEDO XR (
96% PVU;99% de novo) - reported overall satisfaction with AUSTEDO XR (
91% PVU;89% de novo)
These survey results highlight the positive patient experience with AUSTEDO XR, demonstrating that, as a result of reduced motor symptoms, patients living with TD experienced improvement in overall quality of life, including physical, social and emotional well-being. The overall patient satisfaction with AUSTEDO XR as a treatment option is further demonstrated by the fact that >
Full results were presented at the Psych Congress Annual Meeting on September 20, 2025.
About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.1,2,3
About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets
AUSTEDO XR and AUSTEDO® are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.
INDICATIONS AND USAGE
AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia.
IMPORTANT SAFETY INFORMATION
Depression and Suicidality in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.
Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.
Clinical Worsening and Adverse Events in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.
QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.
Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.
Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.
Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.
Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.
Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.
Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.
Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>
Please see accompanying full Prescribing Information, including Boxed Warning.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
References:
- Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Hauppauge, NY: Nova Science Publishers. 2013:235-258.
- Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11.
- Tardive dyskinesia. National Alliance on Mental Illness website. https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Accessed May 4, 2023.
Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquiries TevaIR@Tevapharm.com
FAQ
What were the key findings of the AUSTEDO XR patient survey by Teva (NYSE: TEVA)?
How many patients participated in the AUSTEDO XR tardive dyskinesia study?
What percentage of AUSTEDO XR patients reported improved social and emotional well-being?
What was the patient satisfaction rate with AUSTEDO XR for tardive dyskinesia?
When were these AUSTEDO XR results presented?
